Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy
Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy
Not yet recruiting · NCT07310186 · Registry updated 2025-12-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Not stated | 2025-12-30 | NCT07310186 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking Union Medical College Hospital | 417 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||